a Included all enrolled patients who received ≥1 dose of PF-06801591, had measurable disease baseline assessment (within 28 days prior to study entry) and ≥1 post-baseline assessment or disease progression or death before the first tumor assessment. b Total includes patients with low or high PD-L1 expression, and those with not determined PD-L1 expression. c Among the 7 partial responders, 6 partial responders had confirmed best overall response of PR; 1 patient achieved partial response but disease progressed in the next subsequent tumor scan by RECIST 1.1, and non-determined by irRECIST. CI, confidence interval; mITT, modified intent-to-treat; irRECIST, immune-related Response Evaluation Criteria in Solid Tumors.
